Avisa Diagnostics Inc. operates a clinical-stage medical device company. It is developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company offers clinical proof-of-concept through trials in cystic fibrosis, tuberculosis, and community-acquired pneumonia.

It also provides bacterial infections, including COPD, cystic fibrosis (CF), non CF bronchiectasis, community acquired pneumonia, and tuberculosis. It focuses on pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia. Avisa Diagnostics Inc. is based in Vancouver, Canada.